Esophagogastric Adenocarcinoma research hub

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

This study looks at a new way to treat stomach (gastric) and food pipe (oesophageal) cancer. It combines chemotherapy with an immunotherapy drug called durvalumab, given before surgery and again afterwards, to see if it improves patient outcomes.